CTRI/2022/11/047688
Not Yet Recruiting
N/A
High-throughput, affordable newborn screening for Inborn Errors of Metabolism using Tapestry
Algorithmic Biologics Private Limited0 sites0 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Algorithmic Biologics Private Limited
- Status
- Not Yet Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects whose Guardians are willing to give written informed consent for study participation
- •Subjects who are ready to comply with the study related procedures
Exclusion Criteria
- •Any active illness, psychological and/or pathological condition that would interfere with study participation in the opinion of the Investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Research on newborn screening for treatable neonatal and childhood diseasesprimary immunodeficiency, spinal muscular atrophyJPRN-UMIN000045633Tokyo Medical and Dental University
Recruiting
N/A
establishing newborn screening program for metabolic disorders in Udupi DistrictHealth Condition 1: null- all newborns 48 hours old also includes,doctors nurses anganwadi workersCTRI/2017/09/009912Vision Group Science and Technology
Recruiting
N/A
Establishment of expanded newborn screening system in Tokyo metropolitaSpiral Muscular Atrophy, Severe Combinede Immunodeficiency, Pompe Disease, Mucopolysaccharidosis type I &II, Fabry diseaseJPRN-UMIN000048900Department of Pediatrics, The Jikei University School of Medicine4,000
Not Yet Recruiting
N/A
Genetic Newborn Screening for Rare Diseases within the Screen4Care Projectgenetic newborn screeningDRKS00033501niversitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen20,000
Recruiting
N/A
Setting the stage for newborn screening and gene therapy: a disease-specific retrospective survey of FHL2 and 3Familial Hemophagocytic Lymphohistiocytosis 2/3DRKS00028493niversitätsklinikum FreiburgCentrum für Chronische Immundefizienz (CCI)im Zentrum für Translationale Zellforschung200